This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
Twenty-five clinically-structured protocols — reviewed by licensed physicians, verified by Finnrick, shipped within 24 hours of approval.
Pre-combined at manufacturing — single vial, precise ratios, COA covers every analyte. Formulated to address overlapping mechanisms simultaneously.
The foundational recovery stack — local repair at the injury site via BPC-157, systemic tissue remodeling via TB-500. Two complementary mechanisms in one vial.
Adds GHK-Cu's collagen-signaling and gene-regulation activity to the Wolverine foundation — targeting skin, wound healing, and systemic regeneration together.
Builds on GLOW with KPV — an NF-κB inhibitor that directly penetrates gut epithelial cells. Full-spectrum repair: skin, tissue, systemic inflammation, and gut barrier.
Each protocol is independently structured with physician-reviewed dosing, mechanism summary, and stack guidance.
Receptor agonists targeting appetite, glucose regulation, and metabolic function
GLP-1 receptor agonist. STEP 1 trial: 14.9% mean weight reduction. Titration from 0.25mg to 2.4mg weekly over 20 weeks.
View protocol → Dual GIP + GLP-1Dual GIP + GLP-1 agonist. SURMOUNT-1: 22.5% weight reduction at 15mg. 47% greater loss than semaglutide in head-to-head.
View protocol →Long-acting amylin receptor agonist (CALCR/RAMP1) — different receptor from all GLP-1 drugs. Phase 2: ~15% monotherapy weight loss. Additive to GLP-1 agonists (REDEFINE program: ~22% combined).
View protocol → GLP-1 / Glucagon DualDual GLP-1R + GcgR agonist — glucagon receptor activation drives thermogenic fat burning beyond appetite suppression. Phase 2: ~19% weight loss, 83% MASH resolution. Boehringer Ingelheim SYNCHRONIZE program.
View protocol →Modified GH fragment (176-191) — targets β3-adrenergic receptors in adipose tissue to drive lipolysis without IGF-1 elevation, GH suppression, or glucose effects. GRAS status; Phase I/II completed in Australia.
View protocol →Small molecule NNMT inhibitor — preserves NAD+ in adipocytes by blocking nicotinamide methylation, activates SIRT1, and shifts white fat cells toward oxidative metabolism. Nature Communications 2021: ~6% fat loss in 9 days (mice), no lean mass loss.
View protocol →Peptides that preserve or stimulate endogenous GH pulsatility without suppressing the pituitary feedback loop
GHRH (1-29) fragment — stimulates natural pulsatile GH release. Preserves pituitary feedback; historically FDA-approved as Geref.
View protocol → GHRP + GHRHDual-pathway GH stack — ipamorelin targets ghrelin receptors while CJC-1295 (no DAC) extends the GHRH pulse for amplified, physiologic GH release.
View protocol → GHRH AnalogueFull GHRH 1-44 analogue — FDA-approved as Egrifta (2010) for visceral fat reduction. More potent and longer-acting than sermorelin. Phase III: 15–20% trunk fat reduction. Emerging cognitive research.
View protocol → IGF-1 AnalogueLong-acting IGF-1 analogue with Arg³ substitution that eliminates IGFBP binding — 20–30 hour half-life vs ~10 minutes native. ~3× effective potency. Downstream mediator of GH's anabolic and tissue-repair effects.
View protocol → GHRP — Most PotentThe most potent GHRP — maximum GH pulse amplitude via GHS-R1a without appetite stimulation. Second receptor target: CD36 on cardiac tissue drives cardioprotective effects independent of GH release. No other GHRP has this dual mechanism.
View protocol →Tissue repair peptides targeting local injury sites and systemic healing mechanisms
Body Protection Compound — 15-amino acid peptide derived from gastric protein. Accelerates tendon, ligament, muscle, and gut tissue repair via angiogenesis and nitric oxide pathways.
View protocol → RecoveryThymosin Beta-4 fragment (LKKTETQ) — promotes actin polymerization, cell migration, and systemic tissue regeneration across muscle, tendon, and cardiac tissue.
View protocol →Peptides targeting collagen synthesis, telomere biology, and cellular aging mechanisms
Copper tripeptide-1 — influences gene expression, stimulates collagen and elastin synthesis. Dr. Loren Pickart research: modulates 31.2% of human genes studied.
View protocol → LongevityTetrapeptide (Ala-Glu-Asp-Gly) from Dr. Khavinson's pineal gland research. Associated with telomerase activation in vitro and circadian/melatonin regulation.
View protocol →16-amino acid mitochondria-encoded peptide — activates AMPK and SIRT1, improves insulin sensitivity and metabolic flexibility. Dr. Pinchas Cohen, USC. Cell Metabolism 2015. Anti-aging and metabolic research.
View protocol → SenolyticSenolytic peptidomimetic that disrupts the FOXO4-p53 survival signal in senescent "zombie" cells — triggering selective apoptosis in cells that drive chronic inflammation (SASP). Baar et al., Cell 2017. Mouse data; no human trials.
View protocol → AntioxidantThe body's master antioxidant — injectable formulation bypasses poor oral bioavailability for direct cellular delivery. Supports liver Phase II detoxification, mitochondrial protection, NK cell function, and NAD+ conservation. 600mg and 1,500mg vials.
View protocol →Neuropeptides targeting anxiety, BDNF expression, cellular energy, and cognitive performance
Heptapeptide anxiolytic — GABA-A modulation without the sedation or dependency profile of benzodiazepines. Approved anxiolytic in Russia. Intranasal or subcutaneous.
View protocol → NootropicACTH 4-10 fragment — upregulates BDNF and TrkB receptor expression without adrenal or cortisol involvement. Approved nootropic in Russia. Often paired with Selank.
View protocol → Cellular EnergyEssential coenzyme — declines ~50% between ages 40 and 60. Supports sirtuin activation, mitochondrial function, DNA repair, and cognitive clarity. Injectable or oral precursors.
View protocol →Peptides targeting sexual function and performance through central nervous system pathways
Melanocortin receptor agonist — activates the dopamine pathway to enhance sexual desire, not vascular function. FDA-approved as Vyleesi for HSDD in women (2019).
View protocol → Performance / AppearanceNonselective melanocortin agonist — MC1R drives UV-independent skin pigmentation; MC4R drives sexual arousal. The precursor molecule to PT-141, with the addition of a tanning effect.
View protocol → Hormonal / HPG AxisMaster regulator of the HPG axis — triggers GnRH → LH/FSH → testosterone/estrogen cascade via GPR54. Preserves endogenous testosterone production. 35+ human trials. GPR54 knockout = infertility.
View protocol →Peptides that modulate innate and adaptive immunity through thymic and toll-like receptor pathways
Our AI searches the full Cinch Bio research library — peptide mechanisms, clinical data, dosing protocols, and stack combinations — then reasons across sources to answer your question. Not a search engine. An agent.
Educational information only. Not medical advice. All protocols at Cinch Bio require physician review and a valid prescription before dispensing. The AI assistant searches peer-reviewed research and product documentation — it is not a physician.